Highly potent APIs are becoming more significant across the pharmaceutical development pipeline. Market estimates vary, but the direction is consistent: the global HPAPI market hit around USD 29.87 billion in 2025 and forecasts growth to USD 48.29 billion by 2033[RG1.1], driven by demand for targeted medicines, oncology therapies and other potent molecules.
For oral drug products, however, the challenge is not simply to handle HPAPI safely. Whether the intended medicine is a tablet, capsule, or liquid formulation, success depends on integrating toxicology, formulation science, process engineering, containment and lifecycle planning from the outset.
An isolator, negative-pressure suite or stated occupational exposure band (OEB) may be an important part of the answer. None, in isolation, demonstrates that a product can be manufactured safely, reproducibly and at commercial scale. The more meaningful test is whether the proposed operating model protects people, prevents crosscontamination, preserves critical quality attributes and remains practical through development, technology transfer and routine supply.
Starting With Exposure
Containment discussions often begin with an OEB designation, such as OEB 4 or OEB 5. Although useful as an operational shorthand, OEBs are not universally harmonised across the industry and should not replace compound-specific assessment.
The starting point is the occupational exposure limit, or OEL: the average airborne concentration of an API considered acceptable over a defined period, commonly an eight-hour time-weighted average. The OEL defines the exposure outcome that a control strategy must achieve. It does not prescribe a particular piece of equipment, room classification or facility layout.
Other toxicological limits also inform manufacturing decisions. Permitted daily exposure (PDE), also known as acceptable daily exposure (ADE), is relevant to the assessment of product carryover, crosscontamination and cleaning limits in multiproduct facilities. The no-observedeffect level may contribute to defining an acceptable daily exposure where appropriate toxicology data are available.
These distinctions have practical implications. Two products within the same broad OEB may require different containment strategies because they differ in batch size, particle characteristics, powder flow, dose, route of administration, process route and handling requirements. A fine, cohesive and electrostatically charged powder handled through multiple open transfers presents a different risk profile from a material processed through closed charging and transfer systems.
